Grifols Continues to Grow in Africa and Will Build a Plant in Nigeria

Grifols continues its expansion in Africa. The Spanish pharmaceutical company, which specializes in the production of plasma derivatives, announced Monday, July 19th, that it will build an intravenous solutions production plant in Nigeria for Dozie and Dozie’s Pharma, a supplier of medical devices in the country and the region.

Upon completion of the first phase of the facility in 2024, the plant, which will be located in southeastern Nigeria, will be able to produce up to 5.5 million bags of intravenous solutions per year for use in hospitals and other healthcare institutions in Nigeria and other African countries.

Grifols Engineering, which has extensive worldwide experience in the construction of advanced and specialized production facilities for the healthcare and biotechnology sectors, will design the plant and provide the clean rooms and equipment necessary to carry out the processes. The facilities will have sufficient capacity to double production and meet the expected growth in demand, according to Grifols.

Read more about Grifols and its plans to build a new plant in Nigeria with our companion app Born2Invest. Stay on top of the market with the latest business news brought to you by our experienced team of journalists.

Grifols strengthened its presence in Africa by signing a strategic alliance with the Egyptian government in November 2020

“We are very pleased to have been selected by Dozie and Dozie’s Pharma to build a state-of-the-art manufacturing plant for intravenous solutions that will improve the delivery of healthcare services in Nigeria and West Africa,” says Daniel Fleta, Grifols’ industrial director.

Grifols strengthened its presence in Africa with the signing, in November 2020, of a strategic alliance with the Egyptian government to develop the local plasma therapy market, which includes the opening of twenty plasma donation centers and the construction of a plasma fractionation plant and a purification, dosing and conditioning plant. Africa will benefit from these infrastructures aimed at strengthening the self-sufficiency of plasma derivatives in the region.

The company has also designed and set up a plasma collection center and modular laboratories in Liberia as part of its efforts to combat Ebola, and is finalizing the construction of an intravenous solutions plant in Morocco, after completing its design and refurbishment.

The pharmaceutical company is also present in other African countries such as Liberia and Egypt

The total economic impact of Grifols in the main countries where it operates is estimated at $8.85 billion (€7.5 billion) and 140,000 jobs generated, including direct, indirect, and induced employment.

Headquartered in Abuja (Nigeria), Dozie and Dozie’s Pharm is a company created in 1990. It was formed with the objective of making research-based specialty drugs available to customers in Nigeria and other parts of Africa. It has focused on importing drugs in various areas such as oncology and immunology, among others. Due to the huge success of this business, the company is moving towards total exclusivity of specialty drugs in almost all hospitals, as well as major private clinics and government institutions and agencies.

__

(Featured image by kkolosov via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.